- About
- Resource Library
- Collections
- Events
Long-Acting Injectable Antipsychotics & The Evolving Healthcare Landscape Post-COVID-19 Pandemic For Patients With Schizophrenia & Bipolar I Disorder
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Long-Acting Injectable Antipsychotics & The Evolving Healthcare Landscape Post-COVID-19 Pandemic For Patients With Schizophrenia & Bipolar I Disorder
Schizophrenia and Bipolar Disorder have a significant burden that is expected to have escalated due to COVID-19. People with serious mental illness are at increased risk of COVID-19 and have higher rates of hospitalization, morbidity, and mortality. Drs. Correll and Chen will discuss how the pandemic has affected patients with schizophrenia and bipolar disorder, including access to long-acting injectable antipsychotics.
Moderator:
Gina Lau, PharmD
Regional Medical Lead, Otsuka Pharmaceutical Development & Commercialization, Inc.Featuring
-
Christoph Correll, MD
Professor of Psychiatry and Molecular Medicine; The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY; Professor and Chair; Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy; Charité University Medicine Berlin, Berlin, Germany
-
Maxine Chen , PhD
Director, U.S. Medical Affairs, Otsuka Pharmaceutical Development & Commercialization
-
Gina Lau, PharmD (OPDC)
Regional Medical Lead
Christoph Correll, MD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. Maxine Chen, PhD and Gina Lau, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc.
Related Events
Registration
Already registered?Already registered?
- Resource Library
